Top

Published in:

Open Access 01-01-2015 | Original Paper

Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer

Authors: Yunlang Cai, Jingmei Wang, Lin Zhang, Di Wu, Dandan Yu, Xiaoqiang Tian, Jun Liu, Xinru Jiang, Yang Shen, Lihua Zhang, Mulan Ren, Peilin Huang

Published in: Medical Oncology | Issue 1/2015

Abstract

The present study was designed to explore the cross talk between fatty acid synthase (FASN) and HER2 (ErbB2) in ovarian cancer. A total of 60 ovarian cancer patients and 15 normal ovarian tissues were enrolled. Tissue array was conducted by using a tissue microarray instrument. Immunohistochemistry was performed to quantify the expressions of HER2 and FASN. The FASN was detected to be distributed in the cell cytoplasm and was significantly correlated with cancer grade (p = 0.000) and FIGO staging (p = 0.000). Patients with FASN overexpression in ovarian cancer tend to have a worse overall survival rate (p = 0.000). HER2 was also stained to be distributed in the cell cytoplasm associated with higher expression in high-grade cancer. It was also disclosed that FASN expression level is not correlated with HER2 status in ovarian cancer. These results for the first time indicated that a cross talk in FASN and HER2 expressions might be associated with prognosis in malignant ovarian cancer.

Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–77.PubMedCrossRef

Li N, Bu X, Tian X, Wu P, Yang L, Huang P. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway. Nutr Cancer. 2012;64:864–70.PubMedCrossRef

Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, et al. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. Br J Cancer. 2012;107:300–7.PubMedCentralPubMedCrossRef

Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999;26:51–9.PubMed

Li N, Lu H, Chen C, Bu X, Huang P. Loss of fatty acid synthase inhibits the “HER2-PI3K/Akt axis” activity and malignant phenotype of Caco-2 cells. Lipids Health Dis. 2013;1:83.CrossRef

Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, et al. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun. 2013;385:454–9.CrossRef

Malthièry Y, Savagner F. Energy metabolism of the cancer cell: example of mitochondria-rich endocrine tumors. Ann Endocrinol (Paris). 2006;67:205–13.CrossRef

Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC, et al. The expression of fatty acid synthase (FASE) is an earlyevent in the development and progression of squamous cell carcinoma of the lung. Hum Pathol. 2000;31:1068–73.PubMedCrossRef

Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26:5713–20.PubMedCentralPubMedCrossRef

10.

Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1:707–15.PubMed

11.

Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000;60:213–8.PubMed

12.

Gansler TS, Hardman W 3rd, Hunt DA, et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol. 1997;28:686–92.PubMedCrossRef

13.

Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology. 2005;68:154–61.PubMedCrossRef

14.

Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, et al. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol. 2005;94:735–9.CrossRef

15.

Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F, et al. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol. 2004;92:887–95.PubMedCrossRef

16.

Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol. 2004;95:89–94.PubMedCrossRef

17.

Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003;98:66–73.PubMedCrossRef

18.

Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R. Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol. 2005;124:392–401.PubMedCrossRef

19.

Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol. 2004;15:104–12.PubMedCrossRef

20.

Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 2008;41:59–85.PubMedCrossRef

21.

Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, et al. Inhibition of fatty acid synthase (FAS) suppresses Her2/neu (ErbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA. 2004;101:10715–20.PubMedCentralPubMedCrossRef

Title: Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer
Authors: Yunlang Cai
Jingmei Wang
Lin Zhang
Di Wu
Dandan Yu
Xiaoqiang Tian
Jun Liu
Xinru Jiang
Yang Shen
Lihua Zhang
Mulan Ren
Peilin Huang
Publication date: 01-01-2015
Publisher: Springer US
Published in: Medical Oncology / Issue 1/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0391-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice

Hyaluroan-regulated lymphatic permeability through S1P receptors is crucial for cancer metastasis

Texosome-anchored superantigen triggers apoptosis in original ovarian cancer cells

Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma

Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer

Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page